Table 4.
Multivariate Cox proportional hazards model for time-to progression (TTP), and overall survival (OS)
| Time-to progression |
OS |
|||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | P | HR | 95 % CI | P | |
| BRCA status | ||||||
| BRCA1 positive vs. negative | 0.83 | 0.47–1.49 | 0.28 | 1.21 | 0.60–2.43 | 0.44 |
| BRCA2 positive vs. negative | 1.73 | 0.81–3.71 | 0.44 | 0.10–1.86 | ||
| Clinical stagea | ||||||
| IV vs. I | 0.57 | 0.30–1.08 | 0.001* | – | – | – |
| III vs. I | 1.89 | 1.01–3.54 | ||||
| II vs. I | 1.05 | 0.59–1.86 | ||||
| Site of first metastasis | ||||||
| Visceral vs. bone-only | 2.90 | 1.69–4.97 | 0.003 | – | – | – |
| Mixed vs. bone-only | 3.66 | 2.16––6.21 | <0.0001 | |||
| Nodal status | ||||||
| N3 vs. N0-2 | – | – | – | 2.69 | 1.49–4.88 | 0.0003 |
| Nuclear grade | ||||||
| 3 vs. 1/2 | – | – | – | 2.89 | 1.39–6.01 | 0.005 |
| Triple-negative | ||||||
| Yes vs. no | – | – | – | 2.15 | 1.19–3.90 | 0.001 |
| Bisphosphonates use | ||||||
| Yes vs. no | – | – | – | 0.55 | 0.30–0.99 | 0.03 |
HR hazard ratio, CI confidence interval
*
P value for overall effect
a
Clinical stage at initial diagnosis